Scolr Pharma’s CEO resigns
The company will be managed by its existing executive management team on an interim basis. Michael Taglich, chairman of the board of Scolr Pharma, said: “On behalf of
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death protein 1 (PD-1) or PD-L1 antibodies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).